ALIM RSI Chart
Last 7 days
-9.8%
Last 30 days
-9.6%
Last 90 days
-6.1%
Trailing 12 Months
30.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 90.2M | 0 | 0 | 0 |
2023 | 55.8M | 58.7M | 68.5M | 80.8M |
2022 | 59.7M | 52.6M | 54.1M | 54.1M |
2021 | 47.5M | 59.2M | 58.8M | 59.0M |
2020 | 55.6M | 54.8M | 54.4M | 50.8M |
2019 | 49.9M | 50.0M | 51.7M | 53.9M |
2018 | 38.9M | 39.3M | 40.6M | 46.6M |
2017 | 35.1M | 36.0M | 37.4M | 35.9M |
2016 | 24.3M | 28.1M | 29.5M | 34.3M |
2015 | 10.3M | 13.9M | 18.4M | 22.4M |
2014 | 3.5M | 5.1M | 6.8M | 8.4M |
2013 | 0 | 0 | 0 | 1.9M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 26, 2024 | ashman philip | sold (taxes) | -46,354 | 3.83 | -12,103 | president of int'l operations |
Jan 10, 2024 | ashman philip | sold (taxes) | -11,343 | 3.861 | -2,938 | president of int'l operations |
Oct 02, 2023 | eiswirth richard s jr | acquired | - | - | 400,000 | president and ceo |
Oct 02, 2023 | werner jason m. | acquired | - | - | 225,000 | chief operating officer |
Sep 14, 2023 | caligan partners lp | bought | 1,962,810 | 3.39 | 579,000 | - |
Sep 14, 2023 | caligan partners lp | sold | -1,962,810 | 3.39 | -579,000 | - |
Aug 15, 2023 | caligan partners lp | acquired | 6,142,000 | 2.1 | 2,924,760 | - |
Aug 15, 2023 | morgan adam | acquired | 14,379,200 | 1.85056 | 7,770,150 | - |
Aug 15, 2023 | caligan partners lp | acquired | 22,833,700 | 1.7 | 13,431,600 | - |
Aug 15, 2023 | morgan adam | acquired | 7,103,830 | 1.7 | 4,178,720 | - |
Which funds bought or sold ALIM recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | unchanged | - | -5.00 | 55.00 | -% |
May 16, 2024 | Ancora Advisors LLC | new | - | 915,018 | 915,018 | 0.02% |
May 15, 2024 | MARSHALL WACE, LLP | new | - | 332,674 | 332,674 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | added | 45.27 | 26,741 | 112,597 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | new | - | 279,856 | 279,856 | -% |
May 15, 2024 | Royal Bank of Canada | unchanged | - | - | - | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | added | 595 | 456,090 | 542,490 | 0.01% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 288 | 351,788 | 492,020 | -% |
May 15, 2024 | Stonepine Capital Management, LLC | added | 1.29 | -1,478,480 | 15,799,200 | 12.53% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 214 | 2,386 | 3,682 | -% |
Unveiling Alimera Sciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Alimera Sciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Alimera Sciences Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -12.5% | 23,011 | 26,306 | 23,364 | 17,538 | 13,546 | 14,029 | 13,598 | 14,604 | 11,898 | 13,959 | 12,153 | 21,703 | 11,214 | 13,774 | 12,473 | 10,038 | 14,535 | 17,348 | 12,850 | 10,855 | 12,890 |
Gross Profit | -13.3% | 19,658 | 22,680 | 20,606 | 15,113 | 11,518 | 11,904 | 11,592 | 12,438 | 10,218 | 11,993 | 10,464 | 19,890 | 9,652 | 11,782 | 10,936 | 8,553 | 12,608 | 15,075 | 11,271 | 9,681 | 11,290 |
Operating Expenses | 0.0% | 21,960 | 21,956 | 18,752 | 16,321 | 14,820 | 14,012 | 15,003 | 14,412 | 14,365 | 14,745 | 12,486 | 12,887 | 12,082 | 11,609 | 10,529 | 9,852 | 12,390 | 13,648 | 12,987 | 13,271 | 12,685 |
S&GA Expenses | 16.9% | 9,082 | 7,768 | 7,940 | 6,434 | 5,804 | 5,765 | 6,504 | 6,865 | 6,853 | 7,169 | 5,751 | 5,331 | 4,818 | 4,986 | 4,962 | 4,566 | 5,870 | 8,489 | 6,437 | 6,108 | 3,393 |
R&D Expenses | -8.6% | 4,361 | 4,769 | 4,045 | 3,648 | 4,164 | 4,230 | 4,483 | 3,932 | 3,583 | 3,720 | 3,278 | 3,567 | 3,213 | 2,506 | 2,469 | 1,810 | 2,883 | 2,670 | 2,761 | 2,834 | 2,727 |
EBITDA Margin | 264.3% | 0.02* | -0.01* | -0.10* | -0.23* | -0.15* | -0.14* | -0.16* | 0.09* | 0.07* | 0.07* | 0.12* | 0.18* | 0.00* | - | - | - | - | - | - | - | - |
Interest Expenses | -21.4% | 3,739 | 4,754 | 2,070 | 1,694 | 1,667 | 1,634 | 1,500 | 1,383 | 1,364 | 1,363 | 1,360 | 1,347 | 1,343 | 1,452 | 1,285 | 1,351 | 1,292 | 1,173 | 1,232 | 1,236 | 1,228 |
Income Taxes | -557.1% | -32.00 | 7.00 | 53.00 | 25.00 | - | -10.00 | 12.00 | 17.00 | 18.00 | -35.00 | -169 | 640 | 4.00 | -123 | 7.00 | 5.00 | 43.00 | -193 | 77.00 | 261 | 71.00 |
Earnings Before Taxes | -66.5% | -6,283 | -3,774 | -1,301 | -10,004 | -4,968 | -3,781 | -5,245 | -3,098 | - | -4,139 | -4,352 | 8,205 | -3,648 | -1,100 | -611 | -2,541 | -1,155 | 305 | -3,063 | -4,777 | -2,692 |
EBT Margin | 4.6% | -0.24* | -0.25* | -0.29* | -0.41* | -0.31* | -0.30* | -0.31* | -0.06* | -0.07* | -0.07* | -0.02* | 0.05* | -0.17* | - | - | - | - | - | - | - | - |
Net Income | -65.3% | -6,251 | -3,781 | -1,354 | -10,029 | -4,968 | -3,780 | -5,257 | -3,115 | -5,955 | -4,106 | -4,183 | 7,565 | -3,648 | -977 | -618 | -2,546 | -1,198 | 498 | -3,140 | -5,038 | -2,763 |
Net Income Margin | 4.8% | -0.24* | -0.25* | -0.29* | -0.41* | -0.31* | -0.33* | -0.34* | -0.33* | -0.11* | -0.07* | -0.02* | 0.04* | -0.16* | - | - | - | - | - | - | - | - |
Free Cashflow | -115.9% | -587 | 3,685 | -9,830 | -6,158 | -2,218 | -335 | -2,043 | -1,490 | -6,362 | -4,804 | -3,042 | 6,586 | -2,585 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -0.7% | 152 | 154 | 154 | 155 | 48.00 | 43.00 | 43.00 | 48.00 | 50.00 | 59.00 | 60.00 | 62.00 | 46.00 | 51.00 | 49.00 | 49.00 | 49.00 | 50.00 | 47.00 | 50.00 | 52.00 |
Current Assets | 3.9% | 54.00 | 52.00 | 48.00 | 46.00 | 36.00 | 29.00 | 30.00 | 33.00 | 35.00 | 42.00 | 44.00 | 45.00 | 30.00 | 35.00 | 33.00 | 32.00 | 32.00 | 33.00 | 28.00 | 31.00 | 33.00 |
Cash Equivalents | 19.0% | 14.00 | 12.00 | 8.00 | 19.00 | 13.00 | 5.00 | 6.00 | 8.00 | 10.00 | 17.00 | 22.00 | 25.00 | 8.00 | 11.00 | 11.00 | 14.00 | 12.00 | 9.00 | 8.00 | 12.00 | 13.00 |
Inventory | 17.4% | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 |
Net PPE | -3.6% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | 4.2% | 112 | 107 | - | - | - | 63.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Liabilities | -5.1% | 21.00 | 22.00 | 18.00 | 14.00 | 14.00 | 40.00 | 34.00 | 25.00 | 17.00 | 13.00 | 11.00 | 10.00 | 11.00 | 12.00 | 10.00 | 10.00 | 9.00 | 12.00 | 14.00 | 12.00 | 10.00 |
Shareholder's Equity | -11.9% | 41.00 | 46.00 | 49.00 | 46.00 | -18.92 | -20.81 | - | - | - | - | 2.00 | 6.00 | - | - | - | - | - | - | - | - | 1.00 |
Retained Earnings | -1.5% | -424 | -418 | -414 | -412 | -402 | -415 | -411 | -406 | -403 | -397 | -393 | -388 | -396 | -392 | -391 | -391 | -388 | -387 | -388 | -384 | -379 |
Additional Paid-In Capital | 0.2% | 463 | 462 | 462 | 387 | 378 | 378 | 378 | 378 | 378 | 377 | 377 | 376 | 366 | 366 | 353 | 351 | 350 | 350 | 348 | 348 | 347 |
Shares Outstanding | 0.0% | 52.00 | 52.00 | 52.00 | 9.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 6.00 | 7.00 | 6.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 14.00 | - | - | - | 31.00 | - | - | - | 60.00 | - | - | - | 30.00 | - | - | - | 60.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -115.0% | -566 | 3,770 | -9,826 | -5,996 | -2,209 | -251 | -1,913 | -1,598 | -6,213 | -4,683 | -2,732 | 6,692 | -2,501 | -263 | -2,148 | -330 | 548 | 422 | -3,898 | -960 | 284 |
Share Based Compensation | -100.0% | - | 931 | 5.00 | 148 | 226 | 304 | 134 | 43.00 | 312 | 376 | 207 | 16.00 | 262 | 423 | 282 | 21.00 | 440 | -1,711 | 504 | 629 | 770 |
Cashflow From Investing | 75.3% | -21.00 | -85.00 | -4.00 | -75,434 | -9.00 | -84.00 | -130 | 108 | -149 | -121 | -310 | -106 | -84.00 | -85.00 | -318 | -192 | -25.00 | -24.00 | -111 | -24.00 | -15.00 |
Cashflow From Financing | 3903.8% | 2,967 | -78.00 | -546 | 87,125 | 9,998 | -193 | 55.00 | -102 | -62.00 | -19.00 | -49.00 | 9,948 | -57.00 | -46.00 | -110 | 1,623 | 2,415 | 1,069 | -58.00 | -32.00 | -110 |
Buy Backs | - | - | - | - | -624 | 938 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Condensed Consolidated Statements of Operations [Abstract] | ||
Net revenue | $ 23,011 | $ 13,546 |
Cost of goods sold, excluding depreciation and amortization | (3,353) | (2,028) |
Gross profit | 19,658 | 11,518 |
Operating expenses: | ||
Research, development and medical affairs expenses | 4,361 | 4,164 |
General and administrative expenses | 5,432 | 4,171 |
Sales and marketing expenses | 9,082 | 5,804 |
Depreciation and amortization | 3,085 | 681 |
Total operating expenses | 21,960 | 14,820 |
Loss from operations | (2,302) | (3,302) |
Interest expense and other, net | (3,739) | (1,667) |
Unrealized foreign currency loss, net | (196) | (13) |
Change in fair value of warrant asset | (46) | 14 |
Net loss before income taxes | (6,283) | (4,968) |
Income tax benefit | 32 | |
Net loss | (6,251) | (4,968) |
Preferred stock dividends | (14) | |
Net loss applicable to common stockholders | $ (6,251) | $ (4,982) |
Net loss per share — basic | $ (0.12) | $ (0.71) |
Net loss per share — diluted | $ (0.12) | $ (0.71) |
Weighted average shares outstanding — Basic | 54,356,828 | 7,032,231 |
Weighted average shares outstanding — Diluted | 54,356,828 | 7,032,231 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 14,314 | $ 12,058 |
Restricted cash | 32 | 32 |
Accounts receivable, net | 34,224 | 34,545 |
Prepaid expenses and other current assets | 3,693 | 3,909 |
Inventory | 2,206 | 1,879 |
Total current assets | 54,469 | 52,423 |
Property and equipment, net | 2,377 | 2,466 |
Right-of-use assets, net | 1,060 | 1,124 |
Intangible assets, net | 94,471 | 97,355 |
Deferred tax asset | 102 | 104 |
Warrant asset | 6 | 52 |
Total assets | 152,485 | 153,524 |
Current liabilities: | ||
Accounts payable | 10,308 | 8,252 |
Accrued expenses | 4,779 | 6,192 |
Accrued licensor payment | 5,482 | 7,275 |
Finance lease obligations | 220 | 194 |
Total current liabilities | 20,789 | 21,913 |
Long-term liabilities: | ||
Notes payable, net of discount | 69,436 | 64,489 |
Accrued licensor payments | 15,616 | 15,136 |
Other non-current liabilities | 5,991 | 5,816 |
Total liabilities | 111,832 | 107,354 |
Commitments and contingencies (notes 8 and 15) | ||
Stockholders' equity: | ||
Preferred stock, $.01 par value — 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, none issued | ||
Common stock, $.01 par value — 150,000,000 shares authorized, 52,374,687 shares issued and outstanding at March 31, 2024 and 52,354,450 shares issued and outstanding at December 31, 2023 | 524 | 524 |
Common stock warrants | 4,396 | 4,396 |
Additional paid-in capital | 463,328 | 462,446 |
Accumulated deficit | (424,741) | (418,490) |
Accumulated other comprehensive loss | (2,854) | (2,706) |
Total stockholders’ equity | 40,653 | 46,170 |
Total liabilities and stockholders’ equity | $ 152,485 | $ 153,524 |
 | Mr. Richard S. Eiswirth Jr. |
---|---|
 | https://alimerasciences.com |
 | Pharmaceuticals |
 | 150 |